Levonorgestrel intrauterine - Allergan

Drug Profile

Levonorgestrel intrauterine - Allergan

Alternative Names: Levosert; LILETTA; LNG20

Latest Information Update: 03 Mar 2017

Price : $50

At a glance

  • Originator Mithra Pharmaceuticals
  • Developer Allergan
  • Class Hormonal replacements; Norpregnanes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menorrhagia; Pregnancy

Most Recent Events

  • 15 Feb 2017 Medicines360 and Allergan announce partnership with 340-B eligible health centers in Puerto Rico and Florida for supply of levonorgesterol intrauterine
  • 15 Feb 2017 Launched for Pregnancy (Prevention) in Puerto Rico (Intrauterine) before February 2017
  • 04 Jan 2017 Allergan and Medicines360 file sNDA for up to four-year duration of use for LILETTA in USA for Contraception (Intrauterine)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top